Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06561048 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 34 → 37 locations Eligibility criteria expanded, about 40 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 40 words
  2. Primary completion pushed from Nov 2026 to Nov 2027 Trial sites expanded: 27 → 34 locations · Completion pushed from Jul 2028 to Dec 2028v6 Show 2 more changesShow less
    • Trial sites expanded: 27 → 34 locations
    • Completion pushed from Jul 2028 to Dec 2028
  3. Trial sites expanded: 17 → 27 locationsv5
  4. Study sites: 1 to 17v4
  5. Primary completion date: Feb 2026 to Nov 2026 Completion date: Sep 2027 to Jul 2028 · Eligibility criteria expanded, about 138 words · Study site revisedv3 Show 3 more changesShow less
    • Completion date: Sep 2027 to Jul 2028
    • Eligibility criteria expanded, about 138 words
    • Study site revised

    See this version in full on ClinicalTrials.gov ↗

  6. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Sep 2024 to Oct 2, 2024v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 2024 to Oct 2, 2024
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).
Trial Details
NCT Number NCT06561048
Lead Sponsor Corvus Pharmaceuticals, Inc.
Conditions Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov